Works by Pricop, L.

Results: 6

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Published in:
Arthritis Research & Therapy, 2019, v. 21, n. 1, p. N.PAG, doi. 10.1186/s13075-019-1882-2
By:
- Deodhar, A.;
- Mease, P. J.;
- McInnes, I. B.;
- Baraliakos, X.;
- Reich, K.;
- Blauvelt, A.;
- Leonardi, C.;
- Porter, B.;
- Das Gupta, A.;
- Widmer, A.;
- Pricop, L.;
- Fox, T.
Publication type:
Article
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Published in:
Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1773-y
By:
- Coates, L. C.;
- Gladman, D. D.;
- Nash, P.;
- FitzGerald, O.;
- Kavanaugh, A.;
- Kvien, T. K.;
- Gossec, L.;
- Strand, V.;
- Rasouliyan, L.;
- Pricop, L.;
- Ding, K.;
- Jugl, S. M.;
- Gaillez, C.
Publication type:
Article
Polysulfone-Polydimethylsiloxane Block Copolymers Containing Si-O-C Bonds.
Published in:
Journal of Macromolecular Science: Pure & Applied Chemistry, 1998, v. 35, n. 4, p. 563, doi. 10.1080/10601329808001997
By:
- HAMCIUC*, V.;
- GIURGIU, D.;
- MARCU, M.;
- BUTUC, E.;
- IONESCU, C.;
- PRICOP, L.
Publication type:
Article
Synthesis and characterization of two Cu(II) complexes with nicotinamide, oxalate, and nitrate as mixed ligands.
Published in:
Journal of Coordination Chemistry, 2024, v. 77, n. 20/21, p. 2337, doi. 10.1080/00958972.2024.2432585
By:
- Pricop, L.;
- Ionita, G.;
- Stanica, N.;
- Enachescu, C.;
- Tanasa, R.;
- Ferbinteanu, M.
Publication type:
Article
Characterization of the Fcy RIIA promoter and 5' UTR sequences in patients with systemic lupus erythematosus.
Published in:
Genes & Immunity, 2002, v. 3, n. 6, p. 47, doi. 10.1038/sj.gene.6363873
By:
- Pricop, L.;
- Li, L.;
- Salmon, J.E.;
- Jacob, C.O.
Publication type:
Article
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study.
Published in:
British Journal of Dermatology, 2021, v. 185, n. 6, p. 1124, doi. 10.1111/bjd.20413
By:
- Gottlieb, A.B.;
- Merola, J.F.;
- Reich, K.;
- Behrens, F.;
- Nash, P.;
- Griffiths, C.E.M.;
- Bao, W.;
- Pellet, P.;
- Pricop, L.;
- McInnes, I.B.
Publication type:
Article

Works by Pricop, L.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Polysulfone-Polydimethylsiloxane Block Copolymers Containing Si-O-C Bonds.

Synthesis and characterization of two Cu(II) complexes with nicotinamide, oxalate, and nitrate as mixed ligands.

Characterization of the Fcy RIIA promoter and 5' UTR sequences in patients with systemic lupus erythematosus.

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study.